New obesity drug ABBV-295 enters early human testing
NCT ID NCT07291232
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests the safety and tolerability of a new injectable drug called ABBV-295 in 48 adults with obesity. Participants will receive either the drug or a placebo over several weeks. Researchers will monitor side effects, changes in body weight, and how the drug moves through the body.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ABBV-295 (injectable drug)
What this could lead to
If successful, this could lead to a new treatment option for obesity that helps with weight loss.
What could go wrong
This is an early Phase 1b study with only 48 people, focused on safety and dosing. It is too soon to know if ABBV-295 will be effective or have serious side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Acpru /Id# 278624
RECRUITINGGrayslake, Illinois, 60030, United States
-
CenExel ACT- Anaheim Clinical Trials /ID# 283200
RECRUITINGAnaheim, California, 92801, United States